Knight Therapeutics (TSE:GUD) Reaches New 12-Month High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD) reached a new 52-week high during trading on Monday . The company traded as high as C$9.74 and last traded at C$9.74, with a volume of 23150 shares changing hands. The stock had previously closed at C$9.45.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$9.50 target price on shares of Knight Therapeutics and gave the stock a “buy” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Buy rating, According to MarketBeat, Knight Therapeutics currently has a consensus rating of “Buy” and an average target price of C$9.50.

Knight Therapeutics Price Performance

The stock has a market cap of C$949.39 million, a price-to-earnings ratio of 161.17, a P/E/G ratio of -1,013.50 and a beta of -0.14. The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86. The company’s fifty day moving average is C$8.43 and its two-hundred day moving average is C$7.06.

Knight Therapeutics (TSE:GUD) last released its quarterly earnings results on Thursday, May 7th. The company reported C$0.13 EPS for the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%.The company had revenue of C$147.59 million for the quarter. As a group, research analysts predict that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.